In this study, we proved that OLEO is able to reduce the glycolytic rate of both primary and metastatic melanoma cells, reducing the expression levels of critical glucose and lactate transporters (glucose transporter-1 (GLUT1) and monocarboxylate transporter-4 (MCT4), respectively) and enzymes, such as PKM2. Here, SLC2A1 is linked to melanoma.